14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AAME vs MURA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Atlantic American Corp (AAME) is the stronger overall head-to-head candidate over Mural Oncology plc (MURA) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AAME carries a Unified Composite Score of 42.1/100 (HOLD) at $1.18 (7.4x Forward P/E, 5.1% operating margin), whereas MURA carries 44.8/100 (HOLD) at $2.03 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While MURA currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. AAME 42.1/100 HOLD), AAME captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (5.1% vs. 0.0% operating margin) and revenue trajectory (+4.8% vs. +0.0% YoY).
Technical & Structure Timing Caution: AAME trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.9); meanwhile MURA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AAME vs MURA. Trailing 12-month operating profitability (AAME 5.1% vs MURA 0.0%) and valuation multiples (AAME 7.4x vs MURA N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Pharmaceutical Preparations value chain with $35.0M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AAME vs MURA Key Questions & Quantitative Answers
As of Nov 16, 2026, Atlantic American Corp (AAME) is the stronger overall head-to-head candidate over Mural Oncology plc (MURA) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AAME carries a Unified Composite Score of 42.1/100 (HOLD) at $1.18 (7.4x Forward P/E, 5.1% operating margin), whereas MURA carries 44.8/100 (HOLD) at $2.03 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MURA currently prints a higher short-term Unified Composite Score (44.8/100 HOLD vs. AAME 42.1/100 HOLD), AAME captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (5.1% vs. 0.0% operating margin) and revenue trajectory (+4.8% vs. +0.0% YoY). Technical & Structure Timing Caution: AAME trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.9); meanwhile MURA is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AAME leads the Growth & Scale pillar: AAME posts +4.8% YoY revenue growth and -59.7% YoY earnings growth on $210M TTM revenue (13.0% gross margin, 5.1% operating margin), compared with MURA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AAME generates $210M in USD-normalized revenue versus N/A for MURA. In operating R&D and SG&A reinvestment, AAME deploys 7.9% of Rev ($17M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MURA.
AAME screens cheaper on headline valuation multiples. AAME trades at 7.4x Forward P/E, 4.5x Trailing P/E, 2.43x PEG, and 0.1x EV/Revenue (11.5% FCF margin), whereas MURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AAME (5.2% ROE) versus MURA (-103.9% ROE) capital efficiency.
In options market volatility and institutional positioning, AAME carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.92β · 116% Vol realized risk). By comparison, MURA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.39β · 16% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.